CDC and FDA work to increase availability of additional RSV vaccine for infants
The federal agencies announced the availability of additional doses of nirsevimab-alip (Beyfortus; Sanofi) for infants at high-risk of infection.
CDC and FDA work to increase availability of additional RSV vaccine for infants: © Artur - stock.adobe.com
The Centers for Disease Control and Prevention (CDC), along with the FDA, have announced the availability of more than 77,000 doses of nirsevimab-alip (Beyfortus; Sanofi), which are being immediately distrusted to hospitals and physicians through the Vaccines for Children Program, as well as through commercial channels.
Nirsevimab-alip is a monoclonal antibody approved by the FDA to protect infants against severe respiratory syncytial virus (RSV).
“Helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young children, families and the health care system remains a priority,” said Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, in a press release. “We will continue to use all our regulatory tools to help bring safe, effective and high-quality medicines to the public.”
The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.
The CDC and FDA are also working with the American College of Obstetricians and Gynecologists, to encourage health care providers to use the RSV maternal vaccine. This immunization can help safeguard infants against RSV prior to birth.
Additionally, the CDC has been urging clinicians to administer the infant vaccine to patients at the highest risk of infection during this shortage period, including infants up to 6 months, as well as American Indian and Alaska Native infants.
“CDC and FDA are committed to expanding access to this important immunization so that more parents have peace of mind during the winter virus season,” said Nirav D. Shah, MD, JD, CDC’s principal deputy director.
Reference:
CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants. CDC. November 17, 2023. Accessed November 17, 2023. https://www.cdc.gov/media/releases/2023/p1116-rsv-doses.html
The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants
April 2nd 2022Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.
Infants exclusively fed breast milk at birth less likely to develop asthma
September 28th 2024Infants were 22% less likely to develop asthma in early childhood if there were only fed breast milk during birth hospitalization, per a study presented at the 2024 AAP National Conference & Exhibition.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
September 13th 2024The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.
